ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy
December 11, 2020 07:55 ET
|
ExCellThera
MONTREAL, Dec. 11, 2020 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...
RenovaCare Awarded New Patents Allowing Greater Versatility of SkinGun™; Sterility in Field Environments; Spray Solutions to Now Include Targeted Cells, Drugs or Hormones
November 19, 2020 08:15 ET
|
RenovaCare, Inc.
ROSELAND, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an “Off-the-Shelf” Allogeneic Stem Cell Product for the Treatment of Diabetic Ulcers
October 28, 2020 20:08 ET
|
APstem Therapeutics
Fremont, CA , Oct. 28, 2020 (GLOBE NEWSWIRE) -- APstem Therapeutics, Inc., a private biopharmaceutical company developing breakthrough stem cell therapies, today announced the completion of an...
Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function
October 26, 2020 07:30 ET
|
BioCardia, Inc.
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months SAN CARLOS, Calif., Oct. 26, 2020 (GLOBE...
RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020
October 22, 2020 16:35 ET
|
RenovaCare, Inc.
ROSELAND, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
September 29, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
RenovaCare Receives FDA Conditional IDE Approval of CellMist™ System and SkinGun™ Device, Enabling Clinical Study for Safety and Feasibility
August 11, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020
August 07, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership
August 04, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia
July 01, 2020 10:20 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...